TaiRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
April 13, 2022 at 05:12 am IST
Share
TaiRx, Inc. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported sales was TWD 5.14 million compared to TWD 3.36 million a year ago. Net loss was TWD 125.61 million compared to TWD 159.39 million a year ago. Basic loss per share from continuing operations was TWD 1.41 compared to TWD 2.41 a year ago. Diluted loss per share from continuing operations was TWD 1.41 compared to TWD 2.41 a year ago.
TaiRx Inc is a Taiwan-based company mainly engaged in the development and research of new drugs. The Company primarily focus on the research and development of cancer treatment drugs and sepsis adjuvant therapy drugs. The Company's main products include CVM-1118, Rexis, Zelnite, TRX-NOC, TRX-920, TRX-711, TRX-105 and others. CVM-1118 and Rexis are in clinical trials, and Zelnite drugs are sold to domestic medical institutions at all levels through distributors.